NervGen Pharma Corp. (NASDAQ:
NGEN) appointed Keith Vendola, MD, MBA, as Chief Financial Officer effective immediately on April 27, 2026.23
Dr. Vendola will lead financial strategy, operations, capital markets, financial planning, corporate development, and strategic initiatives.23
He previously served as CFO at Wugen (Oct 2023-Dec 2025) and IO Biotech, leading its IPO, with over 20 years in biopharma, investment banking, and research.23
Employment terms include $515,000 annual base salary, up to 40% cash bonus, and 812,002 stock options at $3.92.3
NervGen develops NVG-291, a first-in-class therapy for spinal cord injury and neurologic conditions.24
Sources:
2. https://nervgen.com/nervgen-pharma-strengthens-leadership-team-with-appointment-of-keith-vendola-as-chief-financial-officer/
3. https://www.stocktitan.net/sec-filings/NGEN/6-k-nervgen-pharma-corp-current-report-foreign-issuer-73ee78bc9cae.html
4. https://www.tipranks.com/news/company-announcements/nervgen-pharma-names-new-cfo-and-wins-shareholder-backing-for-2026-equity-plan